BPC-157
Also known as: Body Protection Compound-157, Bepecin, PL 14736, Gastric Pentadecapeptide BPC-157
Overview
BPC-157 is a synthetic 15-amino acid peptide derived from a naturally occurring protective protein isolated from human gastric juice. Originally characterized by researchers at the University of Zagreb, it has become one of the most extensively studied research peptides across a broad range of preclinical models. Its exceptional stability in gastric acid allows oral administration, distinguishing it from many therapeutic peptides that require injection.
Mechanism of Action
BPC-157 acts as a pleiotropic cytoprotective peptide, modulating multiple signaling networks simultaneously rather than targeting a single receptor. Key pathways include: VEGFR2 activation driving angiogenesis via the Akt-eNOS cascade; PI3K/AKT pro-survival pathway upregulation; focal adhesion kinase (FAK)-paxillin complex activation enabling cell migration; JAK-2 activation promoting cell survival and growth hormone receptor sensitization; ERK1/2 pathway stimulation promoting cell division; and nitric oxide system modulation. It also upregulates VEGF expression, regulates tight junction proteins (ZO-1), and induces heat shock proteins (HSP70/90) for GI cytoprotection.
Potential Benefits
- Accelerated wound healing and tissue repair across multiple tissue types
- Gastrointestinal protection and gut barrier integrity support
- Musculoskeletal healing including tendons, ligaments, and bone
- Neuroprotective effects in CNS and spinal cord injury models
- Anti-inflammatory activity via prostaglandin and NO modulation
- Angiogenesis promotion to improve blood supply to damaged tissues
- Cytoprotective effects against organ ischemia-reperfusion injury
- Potential gastroprotection and IBD symptom reduction
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 200-500 mcg/day |
| Beginner | 200-250 mcg/day |
| Intermediate | 500 mcg/day |
| Advanced | 750-1000 mcg/day |
| Cycle Duration | 4-8 weeks |
| Cycle Off | 4 weeks |
Can be dosed once or twice daily. Oral administration uses higher doses (1-2 mg/day). Inject near injured tissue for localized effects when possible.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High systemic availability
Most common method. Inject into abdominal fat or near injury site. Typical dose 250–500 mcg 1–2x daily.
Intramuscular Injection High — direct tissue delivery
Preferred for localized injuries (tendon, joint, muscle). Inject near the injury site.
Oral (Capsule/Liquid) Lower but effective for GI conditions
BPC-157 is uniquely stable in gastric acid. Oral administration is preferred for gut healing, IBS, and GI inflammatory conditions.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving BPC-157:
Healing Stack
The gold standard for tissue repair. BPC-157 promotes angiogenesis and tendon healing while TB-500 provides systemic tissue remodeling. BPC-157 250–500 mcg daily + TB-500 2–5 mg 2x/week for 4–8 weeks.
Gut Healing Stack
Targeted GI repair. BPC-157 (oral) heals gut lining and reduces NSAID damage while KPV (oral) provides anti-inflammatory action on intestinal epithelium.
Neuroprotective Stack
Brain and nerve repair. BPC-157 promotes nerve regeneration, Semax enhances BDNF and cognitive function, Selank provides anxiolytic support.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 5mg, 10mg |
|---|---|
| BAC Water | 2ml per 5mg vial |
| Storage | Refrigerate at 2-8°C after reconstitution |
| Shelf Life | 28-30 days refrigerated; do not freeze reconstituted solution |
Need exact syringe measurements?
Amino Acid Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
Side Effects & Safety
- Generally well-tolerated in animal models
- Nausea possible with subcutaneous injection
- No serious adverse events reported in available studies
- Long-term human safety data lacking
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Active Malignancy
Concurrent Anticoagulant Therapy
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Drug Interactions
- Anticoagulants / Antiplatelets:
FDA Safety Information
FDA Category 2 concerns: immunogenicity risk, peptide impurity concerns, limited human safety data.
Pharmacokinetics
| Half-Life | ~4 hours (subcutaneous); oral form has lower systemic availability but direct GI action |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside BPC-157 for potential complementary or synergistic effects:
Learn More
References & Further Reading
- BPC-157 Wikipedia
- BPC-157 Research Overview
- BPC-157 Clinical Profile
- BPC 157 as Therapy: Controlling Angiogenesis and the NO-System
- Gastric pentadecapeptide BPC 157 and musculoskeletal soft tissue healing
- BPC 157 and Wound Healing
- From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management
- Multifunctionality and Possible Medical Application of BPC 157 — Literature and Patent Review
- Tendon, Ligament, and Muscle Injury Therapy with BPC 157 — A Review
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.